MedTrace Logo

Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma

NCT02304289 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-10-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Safety and Pharmacokinetics of Oral Artesunate in patients with advanced hepatocellular carcinoma (HCC)

Conditions

Interventions

DRUG

Artesunate

Oral Artesunate once-daily for 14 days, dose-escalation

Sponsors & Collaborators

  • University Ghent

    collaborator OTHER

  • Anticancer Fund, Belgium

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Hans Van Vlierberghe, MD, PhD · University Ghent

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304289 on ClinicalTrials.gov